Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
8.09
-0.35 (-4.21%)
Aug 26, 2026, 4:00 PM EDT - Market closed
Iovance Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 324.97 | 263.5 | 164.07 | 1.19 | - | - | |
Revenue Growth | 34.55% | 60.60% | 13698.99% | - | - | - |
Cost of Revenue | 167.68 | 173.18 | 93.25 | 1.03 | - | - |
Gross Profit | 157.29 | 90.32 | 70.82 | 0.16 | - | - |
Selling, General & Admin | 149.18 | 152.32 | 152.27 | 106.1 | 104.1 | 83.66 |
Research & Development | 267.71 | 300.27 | 276.23 | 333.19 | 294.78 | 259.04 |
Operating Expenses | 453.45 | 488.53 | 466.1 | 460.72 | 398.88 | 342.7 |
Operating Income | -296.17 | -398.21 | -395.28 | -460.56 | -398.88 | -342.7 |
Interest & Investment Income | 1.95 | 3.11 | 4.51 | 9.44 | 3.46 | 6.46 |
EBT Excluding Unusual Items | -294.22 | -395.11 | -390.77 | -451.12 | -395.42 | -336.24 |
Merger & Restructuring Charges | -5.14 | -5.14 | - | - | - | - |
Gain (Loss) on Sale of Investments | 5.59 | 7.2 | 10.26 | 3.61 | -0.47 | -6.01 |
Other Unusual Items | - | - | 5.5 | - | - | - |
Pretax Income | -293.78 | -393.05 | -375.01 | -447.52 | -395.89 | -342.25 |
Income Tax Expense | -4.26 | -2.07 | -2.83 | -3.48 | - | - |
Net Income | -289.52 | -390.98 | -372.18 | -444.04 | -395.89 | -342.25 |
Net Income to Common | -289.52 | -390.98 | -372.18 | -444.04 | -395.89 | -342.25 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 410 | 357 | 290 | 235 | 159 | 153 |
Shares Outstanding (Diluted) | 410 | 357 | 290 | 235 | 159 | 153 |
Shares Change | 29.62% | 23.28% | 23.28% | 47.64% | 3.82% | 10.92% |
EPS (Basic) | -0.71 | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 |
EPS (Diluted) | -0.71 | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -296.4 | -336.24 | -364.05 | -384.11 | -313.18 | -265.52 |
Free Cash Flow Per Share | -0.72 | -0.94 | -1.26 | -1.63 | -1.97 | -1.73 |
Gross Margin | 48.40% | 34.28% | 43.17% | 13.12% | - | - |
Operating Margin | -91.14% | -151.12% | -240.92% | -38734.99% | - | - |
Profit Margin | -89.09% | -148.38% | -226.84% | -37345.42% | - | - |
Free Cash Flow Margin | -91.21% | -127.61% | -221.89% | -32305.30% | - | - |
EBITDA | -259.6 | -362.27 | -357.64 | -439.14 | -389.57 | -339.59 |
EBITDA Margin | -79.88% | -137.48% | -217.98% | - | - | - |
D&A For EBITDA | 36.56 | 35.94 | 37.63 | 21.42 | 9.31 | 3.11 |
EBIT | -296.17 | -398.21 | -395.28 | -460.56 | -398.88 | -342.7 |
EBIT Margin | -91.14% | -151.12% | -240.92% | - | - | - |
Revenue as Reported | 324.97 | 263.5 | 164.07 | 1.19 | - | - |